---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-135281"
form_type: "8-K"
ticker: null
cik: "0001505512"
company_name: "Regulus Therapeutics Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:36:45.492426+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Regulus Q1 net loss $8.5M; cash $107.7M; RGLS8429 cohort 4 dosed

## Summary
- Net loss of $8.5M ($0.29/shr) vs $7.1M ($0.42/shr) in Q1 2023.
- Cash, equivalents & investments $107.7M at Mar 31, 2024; runway into H1 2026.
- Initiated 4th & final cohort of Phase 1b MAD trial for RGLS8429 in ADPKD; topline from cohort 3 expected mid-2024.
- Closed oversubscribed $100M private placement in Mar 2024 with new and existing institutional investors.
- R&D expense $6.0M (up 22% YoY); G&A expense $2.8M (up 17% YoY).

## SEC filing metadata
- accession: 0001193125-24-135281
- form_type: 8-K
- cik: 0001505512
- company_name: Regulus Therapeutics Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505512/000119312524135281/0001193125-24-135281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505512/000119312524135281/d791133d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-135281
- JSON: https://secwatch.observer/filing/0001193125-24-135281.json
- Plain text: https://secwatch.observer/filing/0001193125-24-135281.txt

## Key facts
- Earnings Releases
  Regulus Therapeutics Inc. reported the first quarter ended March 31, 2024 results: net income $8.5 million, or $0.29 per share (basic and diluted), EPS $0.29 per share (basic and diluted).
  - Period: the first quarter ended March 31, 2024
  - Net income: $8.5 million, or $0.29 per share (basic and diluted)
  - EPS: $0.29 per share (basic and diluted)
  - Result: reported results
  source text: Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505512/000119312524135281/0001193125-24-135281-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.